摘要
目的分析紫杉类联合蒽环类药物新辅助化疗方案在乳腺癌患者中的应用效果。方法选取2018年4月至2021年4月收治的130例乳腺癌患者为研究对象,按照红绿双色球法将其分为对照组(65例,蒽环类药物)和研究组(65例,紫杉类+蒽环类药物)。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的血小板与淋巴细胞比率(PLR)及Ki-67、糖类抗原125(CA125)、血管内皮生长因子(VEGF)水平低于对照组,血清凋亡蛋白酶激活因子(Apaf-1)水平高于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗后,研究组的生活质量综合评定问卷(GQOLI-74)各维度评分高于对照组(P<0.05)。治疗后,研究组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。结论紫杉类联合蒽环类药物新辅助化疗方案治疗乳腺癌患者的效果确切,能有效控制病情进展,且对患者的免疫功能影响较小,有助于提高其生活质量。
Objective To analyze the application effect of taxanes combined with anthracycline neoadjuvant chemotherapy in breast cancer patients.Methods A total of 130 patients with breast cancer admitted from April 2018 to April 2021 were selected as the research objects.According to the red and green double chromosphere method,the patients were divided into control group(65 cases,anthracyclines)and study group(65 cases,taxanes+anthracyclines).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the platelet to lymphocyte ratio(PLR),and the levels of Ki-67,carbohydrate antigen 125(CA125)and vascular endothelial growth factor(VEGF)in the study group were lower than those in the control group,and the apoptosis protease activating factor-1(Apaf-1)level was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After treatment,the scores of each dimension of Generic Quality of Life Inventory-74(GQOLI-74)in the study group were higher than those in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the study group were higher than those in the control group,and the CD8+was lower than that in the control group(P<0.05).Conclusion Taxanes combined with anthracycline neoadjuvant chemotherapy is effective in the treatment of breast cancer patients,it can effectively control the progression of the disease,and has less effect on the immune function of patients,which is helpful to improve their quality of life.
作者
李菲
乔娜
LI Fei;QIAO Na(Pharmacy Department,Northwest Women's and Children's Hospital,Xi'an 710061;Western Pharmacy,Traditional Chinese Medicine Hospital of Yulin,Yulin 719000,China)
出处
《临床医学研究与实践》
2023年第34期78-81,102,共5页
Clinical Research and Practice
关键词
紫杉类
蒽环类
乳腺癌
taxanes
anthracycline
breast cancer
